Journal Browser
Volume | Year
News and Announcements
View All

Roles of Mutant P53 in Cancer Drug Resistance

Submission deadline: 31 August 2024
Special Issue Editors
Bi-He Cai
School of Medicine, I-Shou University, Kaohsiung City, Taiwan
Interests: P53; Drug Resistance in Cancer; Immunotherapy; Stem Cell and Cancer Stem Cell
Special Issue Information

TP53 gene encodes a protein called tumor protein p53 which acts as a critical tumor suppressor. Mutations of p53 are highly found in human cancers, and most of the hotspot mutations of p53 will cause its loss of functions (LOF). LOF of p53 mutants are correlated with high-level of drug resistance. In addition, some of the hotspot p53 mutants also acquire some oncogenic functions called as gain of functions (GOF). GOF of mutants p53 are highly associated with late-stage malignance, greater chemoresistance and multiple drug resistance. In this special issue is focused on targeting of LOF or GOF p53 mutants for developing cancer therapies.

hotspot mutation
loss of functions
gain of functions
multiple drug resistance
Back to top
INNOSC Theranostics and Pharmacological Sciences, Electronic ISSN: 2705-0823 Published by AccScience Publishing